Cite

HARVARD Citation

    Metges, J. et al. (n.d.). O-012The phase 3 KEYNOTE-181 study: pembrolizumab versus chemotherapy as second-line therapy for advanced esophageal cancer. Annals of oncology. p. . [Online]. 
  
Back to record